Canadian Generic Pharmaceutical Association

Home
Canada
Toronto, ON
Canadian Generic Pharmaceutical Association

Call Directions Website

Representing manufacturers and distributors of finished generic pharmaceutical products, manufacturers and distributors of active pharmaceutical chemicals.

The CGPA represents the Canadian-based generic pharmaceutical industry: a dynamic group of companies which specialize in the production of high quality, affordable generic drugs, fine chemicals and new chemical entities.

10/09/2026

When a medicine loses patent protection, the arrival of its first generic competitors can have a significant impact on drug costs.

These 'first-wave' generics are the first generic versions to enter the market for a medicine that doesn't yet have generic competition. And once that happens, the Tiered Pricing Framework rewards additional entrants (a second, then a third) with further price reductions.

That means timely reviews of first-wave generics can translate directly into savings for Canada’s health-care system.

There are currently 70 first-wave generic medicines or combinations under review by Health Canada. Canadian hospital and retail payers spend approximately $4.7 billion annually on their brand-name versions, and CGPA estimates that timely approval and market entry of these generics could generate approximately $2.2 billion in savings in their first year on the market.

That’s why CGPA supports prioritizing first-wave generic submissions when review capacity is constrained.

But prioritization is only part of the solution. Health Canada also needs sufficient review capacity to ensure Canadians can benefit from lower-cost generic competition in a timely and predictable way.

09/30/2026

Health Canada’s backlog of generic drug submissions has more than doubled, from 117 submissions in September 2025 to 250 as of June 2026.

Prioritizing certain submissions can help ensure existing resources are directed toward medicines that can provide the greatest benefit to Canadians. But prioritization doesn’t increase the number of submissions Health Canada can review.

That requires additional capacity.

Health Canada has told generic manufacturers and CGPA that it would hire 40 additional review staff; as of June, 12 had been hired on two-year terms. But CGPA estimates that at least 100 additional full-time generic review staff are needed to eliminate the backlog and restore timely and predictable reviews.

And the need is particularly pressing, because Health Canada faces a growing workload. The department received 1,052 generic drug submissions in 2025–26, a 55% increase over the previous five-year average.

Investing in sufficient review capacity can help lower-cost generic medicines reach Canadians sooner, give manufacturers greater predictability and ensure public and private drug plans can realize potential savings in a timely manner.

Prioritization may help manage the queue, but only sufficient review capacity will adequately address it.

09/21/2026

There are currently 70 first-wave generic medicines or combinations under review by Health Canada, representing billions of dollars in potential savings for Canada’s health-care system.

Canadian hospital and retail payers currently spend approximately $4.7 billion a year on the brand-name versions of these medicines, and CGPA estimates that timely approval and market entry of their generic competitors could generate approximately $2.2 billion in savings for payers in their first year on the market, after patent expiry.

But Health Canada’s growing backlog of generic drug submissions means lower-cost medicines are reaching Canadians later than they otherwise could.

Prioritizing key submissions can help, but prioritization alone won’t solve the underlying problem.

To ensure timely access to billions of dollars in potential savings for Canada’s health-care system, Health Canada needs sufficient review capacity to provide timely and predictable generic drug reviews.

09/04/2026

A reliable drug review system would bring affordable medicines to Canadians faster.

And while that's a worthy goal in and of itself, the benefits of a predictable system extend even further.

Unpredictable review timelines mean companies face greater uncertainty about where and when to invest, making it harder to secure new production mandates and strengthen Canada's domestic pharmaceutical capacity.

A reliable, predictable system would incentivize generic drug manufacturers to invest in Canadian research, manufacturing and product launches.

At a time when supply chains remain vulnerable and geopolitical uncertainty continues to grow, Canada needs a regulatory system that supports both timely access to medicines and long-term investment.

A predictable, well-resourced drug review process is essential to strengthening Canada's pharmaceutical resilience and ensuring Canadians have reliable access to the medicines they need.

08/28/2026

As of August 25, 2026, manufacturers and vendors can use the DIRECT (Drug Intake, Review, Evaluation, Contracts, Transactions) portal to easily create, manage and track submissions to the Ontario Ministry of Health.

DIRECT allows you to quickly access relevant ministry submission guidelines, view current announcements, and maintain your contact information. The portal supports a wide variety of submission types and products, including single source drug products, multiple source drug products, biosimilars, nutrition products, and more.

Guideline‑driven, data‑entry forms ask only the questions needed for your specific submission, helping reduce incomplete submissions. DIRECT also allows you to submit additional information in cases of incomplete submissions and request certain changes to existing products.

DIRECT submissions benefit from an extended deadline where DIRECT new multiple source product submissions are accepted until 11:59 p.m. Eastern Time (ET) on the published deadline date. The 3:00 p.m. deadline remains in effect for new multiple source product submissions sent by email. Deadline dates are available on the Drug Submissions webpage: https://www.ontario.ca/page/drug-submissions

08/20/2026

The arrival of generic semaglutide is renewing the conversation about switching from brand-name medicines to lower-cost generics.

While some patients may be hesitant to make the change, the evidence is clear:

Generic medicines approved by Health Canada are just as safe and effective as their brand-name counterparts. They must meet the same rigorous standards for quality, safety and efficacy before they can be approved.

There is a substantial difference between generics and brand name drugs, but it isn't how well they work. It's how much they cost.

When patients, providers and drug plans embrace lower-cost generic medicines, everyone benefits. Canadians gain access to the same trusted treatments, while public and private drug plans can redirect valuable healthcare dollars to other priorities.

Generics have been helping Canadians access safe, effective and affordable medicines for decades. Generic semaglutide is simply the latest example of how competition can make healthcare more sustainable for everyone.

You can read more here: https://www.benefitsandpensionsmonitor.com/benefits/group-health/generic-semaglutide-sparks-fresh-debate-over-substitution/393874?hsmemberId=22290246&tu=&utm_campaign=&utm_medium=20260716&_hsenc=p2ANqtz--3ug9SysaCArz95z3yJS5SvfTqH4d_ncEkMnZFmBYmGa-7nfQWc8ZLlFq-vNs4-JT4uoDq_BWD87p3PftZ1Fh-QjpDhg&_hsmi=428708421&utm_content=&utm_source=

08/14/2026

Generics Bulletin Highlights the Positive Impact of Supreme Court Patent Ruling

The Supreme Court of Canada’s recent ruling affirming that methods of medical treatment cannot be patented continues to draw attention from the pharmaceutical industry.

In a new article, Generics Bulletin highlights CGPA’s response to the decision and its importance for physicians, patients and Canada’s generic and biosimilar medicines industry.

AS CGPA President Jim Keon says in the article, “By affirming that methods of medical treatment are not patentable, the Supreme Court has preserved physicians’ freedom to exercise their clinical judgment without interference from patent monopolies and has taken a stand against patent evergreening tactics that delay the entry of more affordable generic and biosimilar medicines.”

Read Generics Bulletin’s full coverage of the ruling and CGPA’s response:

https://insights.citeline.com/generics-bulletin/legalandip/cgpa-accentuates-the-positive-after-canadian-supreme-court-patent-ruling-ZGYAPOVW4JATTP4X2QDWFXWKI4/?utm_campaign=Insights%20-%20Generics%20Bulletin%20-%20Daily&utm_source=Eloqua&utm_medium=Email&utm_content=SPARC%20-%20Generics%20Bulletin%20-%20Daily%20-%20FREE&utm_campaignID=&elqcst=272&elqcsid=125

08/06/2026

Jim Keon, President of CGPA, speaks out on behalf of member companies in a must-read Globe and Mail article published yesterday.

In the coverage, Globe reporter Chris Hannay explores the issues surrounding the doubling of Health Canada’s backlog of generic drug applications.

Increasing delays are negatively effecting patients, insurers and generic pharmaceutical companies. Why are the delays increasing so rapidly? What’s being done about it? Why is it not enough?

Read the Globe and Mail article to learn more about the costly delays: https://www.theglobeandmail.com/business/economy/article-health-canada-backlog-generic-drugs-pharmaceuticals/

08/04/2026

The Supreme Court of Canada has reaffirmed a long-standing principle: methods of medical treatment cannot be patented in Canada.

As an active intervener in this case, CGPA welcomes the Court's decision to protect physicians' clinical judgment, take a stand against patent evergreening and support timely access to more affordable medicines for patients and payers.

"This ruling is a win that supports the sustainability of Canada's healthcare system and patient access to cost-saving generic and biosimilar medicines," said CGPA President Jim Keon.

Read our full news release to learn more about what this decision means for patients, healthcare providers and Canada's pharmaceutical system.

https://canadiangenerics.ca/supreme-court-reaffirms-that-methods-of-medical-treatment-are-not-patentable-in-canada/

07/31/2026

The Canadian Generic Pharmaceutical Association welcomes the federal Pharmaceutical and Life Sciences Sector Task Force report and many of its recommendations to strengthen Canada's pharmaceutical sector.

But as the government looks towards implementation, it's essential that generic and biosimilar manufacturers have seats at the table.

"A pharmaceutical and life sciences strategy cannot be effective if it does not include the manufacturers of the medicines that account for more than 80 percent of prescriptions dispensed in Canada and companies that operate most of this country's pharmaceutical manufacturing capacity," said CGPA President Jim Keon.

Read our full news release to learn more about why Canada's generic and biosimilar industries must be part of the next phase of this work.

https://canadiangenerics.ca/cgpa-calls-for-participation-of-generic-and-biosimilar-medicines-industries-in-implementation-of-pharmaceutical-and-life-sciences-task-force-report-recommendations/

Address

4100 Yonge Street, Suite 501
Toronto, ON
M2P2B5

Telephone

+14162232333

Website

http://www.canadiangenerics.ca/

Alerts

Be the first to know and let us send you an email when Canadian Generic Pharmaceutical Association posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.